The therapeutic strategy based on inhibition of IL-6R has been previously published [8–10] and will not be furthermore elaborate in this article, which will be focused on the strategies adopted to prevent COVID-19 spreading among the susceptible cancer patients and their care givers, as well as the Cancer Institute Health workers. The gene discussed is IL6R; the disease is COVID-19.